Trial Profile
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Mitomycin (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms OLYMPUS
- Sponsors UroGen Pharma
- 01 May 2023 Results published in the UroGen media release.
- 01 May 2023 According to UroGen media release, company highlights the results from this study at the American Urological Association Meeting 2023 in Chicago, IL.
- 01 Dec 2022 Results published in the UroGen Pharma Media Release.